PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28603691-1	2016	AIMS: Recommendations for metformin use are dependent on eGFR category: eGFR >45 ml/min/1.73 m2 - "first-line agent"; eGFR 30-44 - "use with caution"; eGFR<30 - "do not use".	Metformin	26-35	epidermal growth factor receptor	Homo sapiens	57-61	
28603691-1	2016	AIMS: Recommendations for metformin use are dependent on eGFR category: eGFR >45 ml/min/1.73 m2 - "first-line agent"; eGFR 30-44 - "use with caution"; eGFR<30 - "do not use".	Metformin	26-35	epidermal growth factor receptor	Homo sapiens	72-76	
28603691-1	2016	AIMS: Recommendations for metformin use are dependent on eGFR category: eGFR >45 ml/min/1.73 m2 - "first-line agent"; eGFR 30-44 - "use with caution"; eGFR<30 - "do not use".	Metformin	26-35	epidermal growth factor receptor	Homo sapiens	72-76	
28603691-1	2016	AIMS: Recommendations for metformin use are dependent on eGFR category: eGFR >45 ml/min/1.73 m2 - "first-line agent"; eGFR 30-44 - "use with caution"; eGFR<30 - "do not use".	Metformin	26-35	epidermal growth factor receptor	Homo sapiens	72-76	
28603691-4	2016	METHODS: In a consecutive cohort of 550 Veterans with diabetes, metformin use and eligibility were assessed by eGFR category, using eGFRcr and eGFRcys.	Metformin	64-73	epidermal growth factor receptor	Homo sapiens	111-115	
28603691-8	2016	Metformin use decreased with severity of eGFRcr category, from 63% in eGFRcr >60 to 3% in eGFRcr <30. eGFRcys reclassified 20% of Veterans into different eGFR categories.	Metformin	0-9	epidermal growth factor receptor	Homo sapiens	41-45